As it looks to emerge from bankruptcy, Mallinckrodt (MNK) has agreed to sell an experimental medicine that until recently was being tested to treat a fatal genetic disorder. But the company has said it will work with the buyer to ensure it remains available to children, an unexpected twist in the latest controversy over access to a rare disease drug.
At issue is a medication called adrabetadex, which the company was studying to combat Niemann-Pick type C, or NPC, a rare progressive genetic disorder characterized by an inability of the body to transport cholesterol and other fatty substances inside of cells. The life expectancy of someone with the condition is about 20 years, but can be much shorter if NPC emerges during infancy.
About the Author Reprints
Good investigating. Seems that Malinckrodt has in a disguised fashion cut an under-handed cheap deal with Mandos / Beren Therapeutics that is linked with Thiel Capital through James Cam. If Thiel has plans to further the drug this would be good – but why the cover-up / secrecy? Should we expect a hot Mandos/Beren IPO ???